Stock listing

NASDAQ:FEMY Femasys Inc. Stock

Home listing (NASDAQ) of Femasys Inc.

Follow Femasys Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:FEMY

$1.24 USD +0.09 (+7.8%)

Close on Nov 20, 2026

Past year -92.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.21 – $1.31 USDNov 20, 2026
Volume
95,627 sharesNov 20, 2026
Market cap
$10.73M USDAt the close on Nov 20, 2026 · price × 8.66M shares outstanding
52-week range
$1.07 – $20.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$296,881 USDMedian day 94,425 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Femasys Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:FEMY · Home$1.24 USD+0.09 (+7.8%)95,627$1.31$1.31$1.21$1.15Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FEMY · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.24+0.09+7.8%$1.31$1.31$1.2195,627
$1.15+0.03+2.7%$1.165$1.203$1.08132,468
$1.12-0.16-12.5%$1.29$1.305$1.07110,551
$1.28-0.14-9.9%$1.43$1.43$1.27131,803
$1.42+0.02+1.4%$1.46$1.54$1.4052,304
$1.40-0.10-6.7%$1.47$1.55$1.3888,010
$1.50+0.07+4.9%$1.44$1.53$1.4281,909
$1.43+0.01+0.7%$1.35$1.51$1.35100,970
$1.42+0.05+3.6%$1.435$1.482$1.3971,834
$1.37+0.06+4.6%$1.32$1.41$1.3072,719
$1.31-0.13-9.0%$1.41$1.42$1.255109,961
$1.44+0.04+2.9%$1.43$1.53$1.3994,425
$1.40+0.08+6.1%$1.34$1.44$1.33160,081
$1.32-0.05-3.6%$1.37$1.42$1.29129,859
$1.37+0.015+1.1%$1.33$1.41$1.3195,116
$1.355-0.055-3.9%$1.40$1.44$1.30110,312
$1.41+0.04+2.9%$1.41$1.44$1.3863,420
$1.37-0.04-2.8%$1.40$1.46$1.32228,710
$1.41-0.09-6.0%$1.47$1.50$1.361110,573
$1.50-0.06-3.8%$1.59$1.59$1.455126,109
$1.56-0.09-5.5%$1.66$1.68$1.46167,719
$1.65-0.02-1.2%$1.66$1.72$1.6432,512
$1.67+0.04+2.5%$1.65$1.77$1.5834,001
$1.63-0.02-1.2%$1.73$1.75$1.5693,691
$1.65-0.085-4.9%$1.70$1.77$1.6058,500
$1.735+0.175+11.2%$1.49$1.81$1.46130,800
$1.56-0.20-11.4%$1.74$1.75$1.465208,700
$1.76+0.01+0.6%$1.76$1.81$1.6735,500
$1.75-0.25-12.5%$2.00$2.02$1.7166,500
$2.00-0.045-2.2%$2.10$2.15$1.92128,500
$2.045+0.045+2.2%$1.99$2.11$1.9467,700
$2.00-0.08-3.8%$2.04$2.05$1.9680,500
$2.08+0.06+3.0%$2.07$2.11$2.0124,100
$2.02-0.03-1.5%$2.05$2.17$1.99228,400
$2.05-0.05-2.4%$2.16$2.19$1.96252,600
$2.10-0.06-2.8%$2.17$2.24$2.1051,900
$2.16+0.07+3.3%$2.19$2.24$2.09114,300
$2.09-0.29-12.2%$2.36$2.36$2.00277,700
$2.38-0.10-4.0%$2.42$2.485$2.3520,700
$2.48+0.05+2.1%$2.43$2.55$2.4336,100
$2.43-0.15-5.8%$2.53$2.616$2.42103,300
$2.58+0.02+0.8%$2.60$2.60$2.5034,100
$2.56+0.03+1.2%$2.55$2.69$2.5573,200
$2.53-0.06-2.3%$2.57$2.633$2.5332,300
$2.59+0.04+1.6%$2.51$2.64$2.5135,000
$2.55+0.01+0.4%$2.56$2.61$2.4565,700
$2.54-0.02-0.8%$2.61$2.736$2.50979,400
$2.56-0.11-4.1%$2.67$2.738$2.5071,200
$2.67-0.11-4.0%$2.84$2.848$2.5929,800
$2.78+0.04+1.5%$2.81$2.826$2.7416,200
$2.74-0.09-3.2%$2.90$2.95$2.6835,500
$2.83+0.15+5.6%$2.71$2.84$2.6746,600
$2.68-0.30-10.1%$2.99$3.086$2.60197,700
$2.98-0.08-2.6%$3.03$3.063$2.9372,900
$3.06-0.04-1.3%$3.10$3.18$3.0156,700
$3.10-0.16-4.9%$3.26$3.39$3.02139,100
$3.26-0.17-5.0%$3.34$3.425$3.21366,800
$3.43+0.23+7.2%$3.22$3.44$3.10231,000
$3.20+0.41+14.7%$2.79$3.35$2.74530,400
$2.79-0.13-4.5%$2.93$3.09$2.73189,800
$2.92+0.07+2.5%$2.88$3.00$2.83110,400
$2.85-0.13-4.4%$3.00$3.06$2.81211,100
$2.98+0.02+0.7%$2.94$3.08$2.86294,400
$2.96+0.23+8.4%$2.64$3.12$2.64584,900
$2.73+0.02+0.7%$2.59$2.82$2.43961,700

Splits

1 split · NASDAQ:FEMY · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:FEMY
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Femasys Inc. news

Femasys Inc. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
29 in the last 12 months · 138 in all · newest Nov 13, 2026 · oldest 2021
Decks
14 decks · latest May 13, 2026

Where Femasys Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:FEMY · Home listing · This pageNASDAQUnited StatesUSD
BOATS:FEMYBOATSUnited StatesUSD

Valuation

EV/sales −4.2× against a median of 3.3×: the lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$8.31M USD
P/E
Loss
EV/sales
−4.2×
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
60.4%
Operating margin
−929.9%
Net margin
−614.7%
Debt to equity
0.2×
Beta vs S&P 500
1.60

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Femasys Inc. · NASDAQ:FEMYUS$10.73M−US$8.31Mn/a−4.2×n/a0.4×−614.7%0.2×1.60
PetVivo Holdings Inc · OTC:PETVUS$11.76MUS$11.75Mn/a10.8×n/an/a−868.6%n/a0.59
Nosa Plugs AB · OMXSTO:NOSAUS$11.60MUS$10.20Mn/a3.3×n/a3.1×−24.5%0.1×n/a
Observe Medical ASA · OSL:OBSRVUS$11.23MUS$12.45Mn/a6.5×n/a3.7×−258.6%0.7×n/a
Arcoma AB · OMXSTO:ARCOMAUS$11.20MUS$8.23M23.5×0.7×6.6×1.5×4.0%0.0×n/a
Health & Life Co., Ltd. · TPEX:1781US$10.93MUS$10.03Mn/a0.8×n/a1.2×−12.7%0.6×n/a
ADM Tronics Unlimited, Inc. · OTC:ADMTUS$9.97MUS$9.77Mn/a3.0×n/a13.4×−4.3%0.0×-1.45
United Health Products, Inc. · OTC:UEECUS$9.69MUS$9.69Mn/an/an/an/an/an/a-0.09
Guided Therapeutics, Inc. · OTC:GTHPUS$9.65MUS$9.68Mn/a14.2×n/an/a−445.9%n/a-0.75
Nestmedic SA · NEWCONNECT:NSTUS$9.65MUS$9.24Mn/a38.8×n/a3.2×−413.6%0.0×n/a
EPS Bio Technology Corp. · TPEX:4183US$9.57MUS$5.77Mn/a0.4×21.4×1.2×−1.6%0.0×n/a
Median of the othersUS$10.45MUS$9.73M23.5×3.3×14.0×3.1×−24.5%0.0×-0.42

Forecasts

1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
16.50 USD · Analysts' mean
EPS, year to Dec 2026
-2.60 · 2 analysts
Revenue, year to Dec 2026
2.09M · 2 analysts

Team and board

Officers

OfficerRole
Kathy Lee-SepsickPresident and Chief Executive Officer
Dov ElefantChief Financial Officer
John CanningChief Operating Officer
James H. LiuChief Medical Officer
Jeffrey MifekChief Clinical and Regulatory Affairs Officer
Jeremy SiposChief Technology Officer

Board

DirectorRole
John MoorheadDirector
Kenneth D. EichenbaumDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−9.9%
Q2 2026Aug 14, 2026 · After close−5.7%
Q1 2026May 8, 2026 · After close−6.0%
Q3 2025Nov 14, 2025 · After close−11.4%
Q2 2025Aug 8, 2025 · After close−13.2%
Q1 2025May 8, 2025−7.0%
Q4 2024Mar 27, 2025 · Before open−12.2%
Q3 2024Nov 12, 2024 · Before open−11.6%
Q2 2024Aug 8, 2024 · Before open−18.1%
Q1 2024May 9, 2024 · Before open−8.6%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 28, 2024 · After close+11.0%
Q3 2023Nov 14, 2023 · Before open−10.6%
Q2 2023Aug 10, 2023 · Before open−6.5%
Q1 2023May 11, 2023 · After close−13.2%
Q4 2022Mar 30, 2023 · Before open−4.2%
Q3 2022Nov 10, 2022 · Before open+6.0%
Q2 2022Aug 10, 2022 · After close−8.1%
Q1 2022May 11, 2022 · After close+2.8%
Q4 2021Mar 24, 2022 · After close−3.9%
Quarter to Sep 30, 2021Nov 10, 2021 · After close+2.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (May 2026)Investor deck24 slidesMay 13, 2026
Investor Presentation (October 2024)Investor deck27 slidesOct 29, 2024
Investor Presentation (August 2024)Investor deck27 slidesAug 30, 2024
Investor Presentation (April 2024)Investor deck29 slidesApril 2024
Investor Presentation (September 2023)Investor deck35 slidesSep 27, 2023
Investor Presentation (June 2023)Investor deck41 slidesJun 26, 2023
Investor Presentation (May 2023)Investor deck41 slidesMay 11, 2023
Investor Presentation (March 2023)Investor deck43 slidesMar 31, 2023
Investor Presentation (October 2022)Investor deck41 slidesOct 20, 2022
Investor Presentation (August 2022)Investor deck40 slidesAug 2, 2022
All 14 decks
DeckKindSlidesDate
Investor Presentation (July 2022)Investor deck40 slidesJul 28, 2022
Investor Presentation (February 2022)Investor deck36 slidesFeb 28, 2022
Investor Presentation (January 2022)Investor deck36 slidesJan 5, 2022
Investor Presentation (July 2021)Investor deck27 slidesJul 13, 2021

Open Decks

Financings

RaiseDate
Private placement of common stock and pre-funded warrants with accompanying warrants
Closed: US$30M raised · US$3.2 a share · Warrants at US$2.95 for 36 months · Laidlaw & Company (UK) Ltd. +1
Dealers: Laidlaw & Company (UK) Ltd. (lead), Lake Street Capital Markets, LLC
Buyers: Nantahala Capital (Led the financing as new institutional investor); Rosalind Advisors, Inc.
Insiders: Members of Femasys' management team participated.
Use of proceeds: Support strategic priorities: executing commercial initiatives, advancing clinical programs and key operational objectives
Aug 14, 2026
Public offering of financing
Closed: US$8M raised · US$0.36 a share · Warrants at US$0.36 for 60 months · Jones +1
Dealers: Jones (co-lead), Laidlaw & Company (UK) Ltd. (co-lead)
Buyers: Jorey Chernett
Insiders: Certain officers bought 87,363 shares and accompanying warrants at $0.5151 per share and accompanying warrant
Use of proceeds: To accelerate commercialization efforts for its FemaSeed and FemBloc fertility and birth control products
Sep 2, 2025
Public offering of common stock
Announced: US$0.85 a share · Jones
Dealers: Jones (lead)
Use of proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital and G&A expenses
May 30, 2025
Private placement of common stock
Announced: US$0.85 a share · Jones
Dealers: Jones (lead)
Insiders: Certain directors and officers buy at a price of $1.02 per share
Use of proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital and G&A expenses
May 30, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$13.00 a share on Jun 17, 2021.

Price
US$13.00 a share
Shares offered
2,650,000 shares of common stock
Offering size
US$34.5 million
Underwriters' option
Up to 397,500 more shares
Listing
FEMY on the Nasdaq Capital Market
Underwriters
Chardan, JonesTrading · In the order on the cover
Shares delivered
On or about Jun 22, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 12, 2021
Filed publiclyMay 14, 2021
Amended onceJun 14, 2021
Shares registered with an exchangeJun 14, 2021
Declared effective by the SECJun 17, 2021
Final prospectus, with the priceJun 21, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2.29M1.63M1.07M1.21M1.18M1.04M929.1K
Cost of revenue872.4K544.9K380.1K441.9K370.4K306.5K223.7K
Gross profit1.42M1.08M691.9K764.3K809.3K731.4K705.4K
Research and development7.58M8.22M7.21M5.81M4.08M4.13M6.91M
Selling, general and administrative6.65M6.33M6.86M5.43M4.26M2.54M3.30M
Operating income-17.6M-17.8M-14.5M-11.6M-8.34M-6.93M-11.6M
Depreciation and amortization342.0K297.3K483.5K561.2K591.1K679.7K1.09M
EBITDA-17.2M-17.5M-14.0M-11.0M-7.75M-6.25M-10.5M
Interest expense1.89M1.60M165.4K13.5K19.2K12.6K9.97K
Income before tax-18.6M-18.8M-14.2M-11.4M-7.53M-6.91M-11.3M
Income tax1.30K9.60K4.34K6.30K4.00K1.80K3.01K
Net income-18.6M-18.8M-14.2M-11.4M-7.54M-6.91M-11.3M
Earnings per share, basic-0.47-0.85-0.93-0.96-1.12-7.20-19.17
Earnings per share, diluted-0.47-0.85-0.93-0.96-1.12-7.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents9.27M3.45M21.7M13.0M24.8M3.32M6.42M
Short-term investments0998.8K
Receivables616.6K488.4K98.9K77.5K84.3K125.8K83.6K
Inventory5.74M3.05M667.1K436.7K208.3K131.4K172.5K
Current assets16.5M8.02M23.2M14.1M25.6M3.86M8.04M
Property, plant and equipment1.90M1.60M1.11M1.48M1.60M1.83M3.86M
Total assets20.7M12.4M27.8M16.9M28.6M7.61M12.6M
Accounts payable1.83M1.42M1.14M510.8K445.5K674.3K481.1K
Current liabilities3.64M8.58M3.05M1.53M1.69M2.89M1.29M
Long-term debt3.18M4.26M182.5K
Total debt4.70M7.44M6.70M543.7K990.2K2.06M1.71M
Total liabilities14.9M10.1M9.40M1.65M2.24M4.08M58.0M
Shareholders' equity5.87M2.30M18.4M15.2M26.3M-51.8M-45.4M
Shares outstanding2.98M23.4M21.7M11.9M11.8M993.1K588.1K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-18.7M-19.4M-11.3M-10.7M-7.93M-4.93M-11.0M
Capital spending-525.0K-761.7K-143.9K-407.5K-306.9K-8.35K-696.5K
Free cash flow-19.2M-20.2M-11.4M-11.1M-8.24M-4.94M-11.7M
Cash from investing-630.1K-847.8K-143.9K-407.5K-306.9K968.3K12.3M
Cash from financing25.1M2.03M20.2M-681.6K29.7M871.6K-127.8K
Share buybacks-60.8K-230.0K0153.2K2.63K
Change in cash5.81M-18.3M8.75M-11.8M21.5M-3.09M1.18M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2026Insider tradeSEC
8-K · Current reportNov 2, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2026Big-stake noticeSEC
424B3 · ProspectusSep 29, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 29, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
S-3 · Registration statementSep 3, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 31, 2026Big-stake noticeSEC
DAug 20, 2026Other filingsSEC
SCHEDULE 13D · Big-stake noticeAug 17, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
8-K · Current reportAug 11, 2026Material contractSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
8-K · Current reportJun 24, 2026Current reportSEC
8-K · Current reportJun 5, 2026Current reportSEC
8-K · Current reportJun 4, 2026Current reportSEC
8-K · Current reportMay 13, 2026Current reportSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026ResultsSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 29, 2026Meeting outcomeSEC
DEF 14A · Proxy statementApr 6, 2026Meeting noticeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
8-K · Current reportApr 1, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 31, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementMar 27, 2026Meeting noticeSEC
3 · Initial statement of ownershipMar 24, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
8-K · Current reportMar 20, 2026Material contractSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 18, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 17, 2026Insider tradeSEC
8-K · Current reportJan 15, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJan 12, 2026Other filingsSEC
424B3 · ProspectusJan 9, 2026Offer documentSEC
CORRESP · Letter to the SECJan 7, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 6, 2026Other filingsSEC
S-3 · Registration statementDec 31, 2025Offer documentSEC
8-K · Current reportDec 23, 2025Current reportSEC
424B3 · ProspectusDec 23, 2025Offer documentSEC
8-K · Current reportDec 18, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 10, 2025Other filingsSEC
CORRESP · Letter to the SECDec 5, 2025Other filingsSEC
S-3/A · Registration statement, amendedDec 4, 2025Offer documentSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
DNov 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
8-K · Current reportNov 10, 2025Current reportSEC
8-K · Current reportNov 7, 2025Material contractSEC
8-K · Current reportNov 3, 2025Current reportSEC
8-K · Current reportOct 21, 2025Current reportSEC
8-K · Current reportOct 17, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeSep 4, 2025Big-stake noticeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
8-K · Current reportAug 26, 2025Material contractSEC
424B5 · ProspectusAug 26, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 26, 2025Other filingsSEC
S-1/A · Registration statement, amendedAug 21, 2025Offer documentSEC
CORRESP · Letter to the SECAug 20, 2025Other filingsSEC
8-K · Current reportAug 20, 2025Current reportSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
S-1 · Registration statementAug 19, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 12, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftAug 8, 2025Other filingsSEC
DRS · Draft registration statementAug 8, 2025Offer documentSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
8-K · Current reportAug 6, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
8-K · Current reportJul 18, 2025Current reportSEC
UPLOAD · Letter from the SECJul 9, 2025Other filingsSEC
8-K · Current reportJul 3, 2025Material contractSEC
S-3 · Registration statementJul 3, 2025Offer documentSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJul 1, 2025Current reportSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Meeting outcomeSEC
8-K · Current reportJun 25, 2025Current reportSEC
8-K · Current reportJun 17, 2025Current reportSEC
DJun 10, 2025Other filingsSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
8-K · Current reportJun 2, 2025Material contractSEC
424B5 · ProspectusJun 2, 2025Offer documentSEC
424B5 · ProspectusMay 29, 2025Offer documentSEC
8-K · Current reportMay 23, 2025Current reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
8-K · Current reportMar 18, 2025Current reportSEC
8-K · Current reportMar 13, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 26, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 26, 2025Big-stake noticeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
8-K/A · Current report, amendedNov 12, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportOct 29, 2024Current reportSEC
8-K · Current reportSep 11, 2024Current reportSEC
8-K · Current reportSep 9, 2024Current reportSEC
8-K · Current reportAug 30, 2024Current reportSEC
8-K · Current reportAug 29, 2024Current reportSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
8-K · Current reportJul 12, 2024Meeting outcomeSEC
8-K · Current reportJun 20, 2024Current reportSEC
DEF 14A · Proxy statementJun 7, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
10-K/A · Annual report, amendedApr 26, 2024Annual reportSEC
8-K · Current reportApr 24, 2024Current reportSEC
S-8 · Registration statement for employee plansApr 5, 2024Offer documentSEC
S-8 · Registration statement for employee plansApr 5, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
8-K · Current reportMar 20, 2024Current reportSEC
8-K · Current reportMar 6, 2024Current reportSEC
8-K · Current reportFeb 28, 2024Current reportSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 13, 2024Insider tradeSEC
8-K · Current reportFeb 6, 2024Current reportSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 11, 2023Other filingsSEC
424B3 · ProspectusDec 8, 2023Offer documentSEC
CORRESP · Letter to the SECDec 6, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 5, 2023Other filingsSEC
S-3 · Registration statementNov 30, 2023Offer documentSEC
8-K · Current reportNov 29, 2023Current reportSEC
3 · Initial statement of ownershipNov 28, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
3 · Initial statement of ownershipNov 22, 2023Insider tradeSEC
DNov 22, 2023Other filingsSEC
SC 13D · Big-stake noticeNov 22, 2023Big-stake noticeSEC
8-K · Current reportNov 21, 2023Management or board changeSEC
8-K · Current reportNov 15, 2023Material contractSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
4 · Change in ownershipNov 1, 2023Insider tradeSEC
8-K · Current reportOct 11, 2023Current reportSEC
8-K · Current reportOct 3, 2023Current reportSEC
424B3 · ProspectusOct 3, 2023Offer documentSEC
8-K · Current reportSep 27, 2023Current reportSEC
8-K · Current reportSep 6, 2023Meeting outcomeSEC

This page holds 200 of 347 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Femasys Inc.’s releases · as of Nov 12, 2026

Common shares
8,656,277
Fully diluted
8,656,277

Fully diluted

LineSharesAs of
Common shares8,656,277Nov 12, 2026

Warrants and options

Lot
Warrants · US$2.95 · expire about Aug 2029
Warrants · US$0.36 · expire about Aug 2030

Share count over time

CountShares
Nov 12, 20268,656,277
Sep 30, 20268,656,277

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
CX Institutional750<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund344K4.0%US$133KMay 31, 2026
Fidelity Series Total Market Index Fund76,5880.88%US$29,640May 31, 2026
Fidelity Total Market Index Fund50,5400.58%US$19,559May 31, 2026
Fidelity Nasdaq Composite Index Fund42,1630.49%US$16,317May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Lee-Sepsick Kathy
Director, Officer: Chief Executive Officer
Buy15,625USD 3.20US$50,000Aug 7, 2026
Elefant Dov
Officer: Chief Financial Officer
Buy15,625USD 3.20US$50,000Aug 7, 2026
Canning John Charles
Officer: Chief Operating Officer
Buy4,375USD 3.20US$14,000Aug 7, 2026
Sipos Jeremy Alexander
Officer: Chief Technology Officer
Buy3,125USD 3.20US$10,000Aug 7, 2026
Mifek Jeffrey Gerald
Officer: Chief Clinical-Medical Affairs
Buy3,125USD 3.20US$10,000Aug 7, 2026

Big stakes

StakeStakeSharesDateFiling
Alumni Capital LP9.99%4.77MSep 4, 2025Schedule 13G
Dauntless Investment Group, LLC9.90%4.4MSep 30, 2025Schedule 13G
Chernett Jorey9.30%3.03MJun 30, 2025Schedule 13G
PharmaCyte Biotech, Inc.7.87%4.93MMar 17, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joshua N. Silverman
Other companies: PharmaCyte Biotech, Inc. (Interim Chief Executive Officer, President, and Director · Since at least Aug 15, 2022); TAO Synergies Inc. (Executive Chairman · Since at least Jun 4, 2021); Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Dec 1, 2020); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 6, 2018); Fabric.AI, Inc. (Chief Executive Officer, Director · Since at least Aug 15, 2016); Marker Therapeutics, Inc. (Director · Nov 28, 2016 – Oct 16, 2018 · Past); Neurotrope Inc (Director · Aug 4, 2016 – Dec 1, 2020 · Past); Protagenic Therapeutics, Inc. (Director · Feb 12, 2016 – Feb 21, 2020 · Past); MGT Capital Investments, Inc. (Director · Dec 31, 2015 – Dec 31, 2015 · Past); National Holdings Corporation (Director · Jul 28, 2014 – Sep 12, 2016 · Past)
Director · Since at least Nov 21, 2023
Keith J Kendall
Other companies: Aquestive Therapeutics, Inc. (CEO and President, Director · Jul 24, 2018 – Mar 10, 2022 · Past)
Director · Jun 14, 2023 – Jun 14, 2023 · Past
Kenneth D. Eichenbaum
Other companies: InfuSystems Holdings, Inc. (Director · Since at least May 16, 2024)
Director · Since at least Mar 18, 2026
Wendy Perrow
Other companies: Bioanalytical Systems Inc (Director · Dec 10, 2015 – Sep 10, 2019 · Past)
Director · Jan 19, 2022 – Jun 21, 2023 · Past
Charles LarsenDirector · Since at least Jun 17, 2021
Christine E ThomasChief Reg & Clinical Officer · Oct 10, 2023 – Jan 28, 2025 · Past
Daniel Scott CurrieChief Operating Officer · Since at least Jul 3, 2023
Dov ElefantChief Financial Officer · Since at least Jul 3, 2023
Edward R UzialkoDirector · Since at least Jun 17, 2021
Gary ThompsonDirector · Jun 17, 2021 – Jun 17, 2021 · Past
All 21 people
PersonSeat
Hoskin Violet Alexandria KelleyVP, Clinical & Medical Affairs · Jun 17, 2021 – Jun 17, 2021 · Past
James H. LiuChief Medical Officer · Since at least Aug 21, 2025
Jeffrey MifekChief Clinical and Regulatory Affairs Officer · Since at least Jul 6, 2026
Jeremy SiposChief Technology Officer · Since at least Dec 16, 2025
John CanningChief Operating Officer · Since at least Mar 30, 2026
John MoorheadDirector · Since at least Oct 30, 2026
John Q Adams JrDirector · Jun 17, 2021 – Jun 8, 2022 · Past
Kathy Lee-SepsickChief Executive Officer, Director · Since at least Aug 7, 2026
Kathy Lee-SepsickPresident and Chief Executive Officer · Since at least Aug 11, 2026
Kelley Stinson NicholasChief Commercial Officer · Since at least Jun 23, 2025
Richard D SpectorChief Commercial Officer · Feb 12, 2024 – Feb 12, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Femasys Inc.